400-998-5282
专注多肽 服务科研

索马鲁肽是一种胰高血糖素样肽-1(GLP-1)类似物,可以促胰岛素分泌并抑制胰高血糖素分泌。由于索马鲁肽能够减少饥饿感、减少饮食、减少卡路里摄入,从而被认为可用于治疗肥胖症。
编号:428739
CAS号:910463-68-2/1997361-85-9/2924330-56-1
单字母:H2N-H-Aib-EGTFTSDVSSYLEGQAA-K(索马鲁肽侧链)-EFIAWLVRGRG-OH
索马鲁肽是一种胰高血糖素样肽-1(GLP-1)类似物,可以促胰岛素分泌并抑制胰高血糖素分泌。由于索马鲁肽能够减少饥饿感、减少饮食、减少卡路里摄入,从而被认为可用于治疗肥胖症。
司美格鲁肽是一种基于肽的治疗药物,属于胰高血糖素样肽-1受体激动剂(GLP-1 RA)类药物。肽是氨基酸的短链,是蛋白质的基本构成单位。司美格鲁肽是天然存在的肽类物质胰高血糖素样肽-1(GLP-1)的合成版本,GLP-1由肠道产生。GLP-1是一种激素,在调节血糖水平中起着关键作用。它能刺激胰腺分泌胰岛素,减少胰高血糖素的产生(胰高血糖素通常会使血糖水平升高),减缓胃排空速度,并促进餐后饱腹感。这些作用共同促进了血糖控制的改善,对2型糖尿病患者尤其有益。司美格鲁肽的设计旨在模拟GLP-1的作用。它经过改良,在体内具有更长的药效,因此给药频率低于天然GLP-1激素。这使得它适合每周给药一次,从而可提高患者对治疗方案的依从性。
Semaglutide is a peptide-based therapeutic that belongs to the glucagon-like peptide-1 receptor agonist (GLP-1 RA) class of drugs. Peptides are short chains of amino acids, which are the building blocks of proteins. Semaglutide is a synthetic version of a naturally occurring peptide called glucagon-like peptide-1 (GLP-1), which is produced in the intestines. GLP-1 is a hormone that plays a key role in regulating blood sugar levels. It stimulates insulin secretion from the pancreas, reduces glucagon production (which normally raises blood sugar levels), slows down the emptying of the stomach, and promotes a feeling of fullness after meals. These effects collectively contribute to improved glycemic control and can be particularly beneficial for individuals with type 2 diabetes. Semaglutide is designed to mimic the effects of GLP-1. It has been modified to have a longer duration of action in the body, allowing it to be administered less frequently than the natural GLP-1 hormone. This makes it suitable for once-weekly dosing, which can improve patient adherence to treatment regimens.
| 编号 | 名称 | CAS号 |
| 432238 | 索马鲁肽主链 | |
| H2N-H-Aib-EGTFTSDVSSYLEGQAAKEFIAWLVRGRG-OH | ||
| 索马鲁肽的主链 | ||





